Lipoprotein (a) and Cardiovascular Disease
The National Heart, Lung, and Blood Institute (NHLBI) convened
a Workshop of investigators on October 31 - November 1, 2002, in Bethesda, Maryland.
The objectives of this workshop were three fold: 1) to provide the scientific
community with the most recent findings on Lp(a); 2) to present the standardization
of LP(a) methods; and 3) to discuss the role of LP(a) in the clinical setting.
Workshop participants recommended that the NHLBI:
the standardization efforts that have been undertaken by the NHLBI such as validation
of the accuracy of the analytical methods, utilization of the primary and secondary
reference materials developed and validated under the NHLBI LP(a) contract and
pursue a common approach to express LP(a) values in all studies.
more basic research to understand the fundamental functions and mechanism of actions
of LP(a) as well as the mechanisms of LP(a) lowering.
- Encourage the development
of animal models to study LP(a).
- Support large clinical and epidemiological
studies, performed with validated analytical methods and sound study design to
establish the clinical relevance and the predictive power of LP(a).
common population-based reference values and LP(a) values for clinical decision.
and implement a clinical study to evaluate the clinical usefulness of lowering
Working Group Members
- John J. Albers,
PhD. Northwest Lipid Research Laboratories, University of Washington, Seattle
Berg, MD, Ullevaal University Hospital, Department of Medical Genetics, Oslo,
- Celina Edelstein, BA, The University of Chicago, Lipoprotein Study
- Jianglin Fan, MD, PhD, Chief of Laboratory and Cardiovascular
Diseases, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba,
- Scott M. Grundy, MD, PhD, Center for Human Nutrition, University
of Texas Southwestern Medical Center, Dallas
- Helen Hobbs, MD, Departments
of Internal Medicine and Molecular Genetics, University of Texas Southwestern
Medical Center, Dallas
- William B. Kannel, MD, MPH, Department of Medicine,
Boston University School of Medicine, Boston
- Marlys L. Koschinsky, PhD,
Department of Biochemistry, Queen's University, Kingston, ON, Canada
M. Kostner, PhD, Institute of Medical Biochemistry, University of Graz, Austria
Kwiterovich, MD, Lipid Research Atherosclerosis Division, The Johns Hopkins Medical
- Santica Marcovina, PhD, ScD, Northwest Lipid Research
Laboratories, University of Washington, Seattle
- Sally P. A. McCormick,
PhD, Department of Biochemistry, University of Otago, Dunedin, New Zealand
D. Morrisett, PhD, Department of Medicine, Baylor College of Medicine, The Methodist
- Daniel J. Rader, MD, University of Pennsylvania School
of Medicine, Philadelphia
- Edward Rubin, MD, Genome Sciences Department,
Lawrence Berkeley National Laboratory, Berkeley
- Frank M. Sacks, MD, Harvard
School of Public Health, Boston
- Ernst Schaefer, MD, Tufts University School
of Medicine, New England Medical Center Lipid Metabolism Laboratory, Boston
Steinmetz, MD, St. Nikolaus Stiftshospital GmbH, Teaching Hospital University
of Bonn, Andernach, Germany
- Gerd Utermann, MD, Institute for Medical Biology
and Genetics, University of Innsbruck, Austria
- Arnold von Eckardstein,
MD, Institute of Clinical Chemistry, University and University Hospital, Zurich,